Does hormonal therapy increase the risk for recurrent venous thromboembolism (VTE) in women?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

A review by Martinelli et al indicates that hormonal therapy, including estrogen-containing agents, does not appear to be associated with recurrent VTE in women younger than 60 years receiving anticoagulation with rivaroxaban or enoxaparin/vitamin K antagonists for confirmed VTE. [95] However, it was noted that abnormal uterine bleeding occurred more frequently with rivaroxaban than with enoxaparin/vitamin K antagonists.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!